VANCOUVER, British Columbia, Oct. 14, 2026 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”), a developer of marijuana and alcohol breath testing technologies, announces that it has filed a provisional patent application in the United States covering a novel rapid point-of-care (“POCT”) marijuana breath test method designed to detect delta-9 tetrahydrocannabinol (“THC”), the primary psychoactive component of cannabis, from breath samples.
The provisional patent application covers new testing methods under development that combine the Company’s proprietary Breath Collection Unit (BCU) and Breath Cartridge (BC) technologies with lateral flow (LF) rapid test platforms and custom-designed components optimized for point-of-care use. The portable BCU is designed to control, collect and concentrate standardized breath samples and efficiently transfer breath analytes into a workflow compatible with screening and analysis technologies. Safety advocates, employers, and industry stakeholders are increasingly seeking cost-effective, rapid point-of-care marijuana screening solutions that can be deployed using established drug-testing workflows, while offering the unique advantage of assessing recent cannabis use through breath samples.
In recent months, Company scientists have advanced research and development efforts to pair its BCU and Breath Cartridge with next-generation lateral flow assay platforms and custom-designed POCT components. The approach combines the BCU’s ability to efficiently capture THC-containing breath aerosols using air-volume control and pressure-assisted concentration onto its proprietary Breath Cartridge, particularly during the period immediately following cannabis consumption, addressing a central challenge in rapid THC detection. By presenting the lateral flow assay with a concentrated, standardized sample rather than an untreated specimen, the BCU and Breath Cartridge is designed to help address the sensitivity limitations associated with detecting THC at the point of collection. The combined approach is being developed with the goal of enabling a cost effective, rapid point-of-care THC breath screening test (a “Rapid Breath Test Kit“) capable of delivering results within minutes from a breath sample.
The proposed POCT workflow is designed to provide a rapid on-site screening result from the initial BCU collection. If the screening result is positive and evidentiary confirmation is required, the BCU can then be used to collect a confirmation sample under chain-of-custody procedures using the Company’s established Marijuana Breath Test (MBT) process. The confirmation sample is analyzed using a validated LC-MS laboratory method, which has been published in the Journal of Analytical Toxicology and is currently in use with clients. Importantly, the establishment of the MBT represents a technological foundation underpinning the Company’s efforts to develop a breath-based point-of-care THC screening test. This proposed approach is intended to combine the speed and convenience of on-site screening with access to a confirmatory laboratory result when required.
The performance of Cannabix’s POCT approach depends on the integrated operation of the BCU, Breath Cartridge and pre-concentration methods—not on any single commercially available test component. This integrated platform provides the foundation for deploying rapid marijuana breath screening in practical, real-world settings. The proposed Rapid Breath Test Kit remains in the early stages of development and will require further technical advancements, including enhanced analytical sensitivity, optimization of sample collection and recovery methods, and the development of a fully integrated testing workflow.
The provisional patent application builds on Cannabix’s proprietary breath-sampling and sample-preparation intellectual property. The development of a practical and cost-effective Rapid Breath Test Kit reflects Cannabix’s ongoing commitment to advancing innovative point-of-care breath testing solutions for real-world applications.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a leading developer of breath-based technologies designed to enhance public safety and reduce impairment-related risks in workplaces, law enforcement, and a range of different settings. The Marijuana Breath Test (MBT) targets delta-9 THC—the primary psychoactive compound in cannabis—in breath, providing a practical solution for identifying recent marijuana use.
The BreathLogix, unmanned alcohol screening solution supports organizations in proactively monitoring alcohol impairment, strengthening safety protocols, and promoting responsible behavior. By delivering innovative, non-invasive screening tools, Cannabix aims to help reduce accidents, improve decision-making, and protect organizations, individuals and the public at large. Visit www.cannabixtechnologies.com
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
For further information, contact the Company at info@cannabixtechnologies.com
Cautionary Statement Regarding Forward-Looking Statements
This news release contains certain “forward-looking statements” and “forward-looking information” within the meaning of applicable This news release contains certain “forward-looking statements” and “forward-looking information” within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). All statements contained in this news release that are not statements of historical fact are forward-looking statements, including, without limitation, statements regarding: the development, performance, validation, commercialization, deployment, market acceptance, and adoption of the Company’s proposed Rapid Breath Test Kit, Marijuana Breath Test (“MBT”), Breath Collection Unit (“BCU”), Breath Cartridge technologies, and BreathLogix technologies; the potential effectiveness of the Company’s BCU-enabled point-of-care marijuana breath testing methods; the ability of the Company’s technologies to collect, concentrate, recover, detect, analyze, or confirm THC or other analytes from breath samples; anticipated customer demand and market opportunities for rapid point-of-care marijuana screening solutions; the integration of lateral flow assay technologies and custom-designed testing components with the Company’s proprietary breath collection platform; the ability to provide rapid screening and laboratory confirmation workflows; intellectual property development, protection, prosecution, and the potential issuance of patents based on provisional or future patent applications; future technological enhancements, product development efforts, and research initiatives; manufacturing scale-up and operational readiness; the Company’s ability to establish and expand reseller, distribution, laboratory, strategic, research, and commercial relationships; expansion into additional drug-testing, workplace safety, regulatory approvals, certifications, and compliance; future financings; and the achievement of anticipated business, commercial, scientific, technical, or operational milestones. Forward-looking statements are often identified by words such as “anticipate,” “believe,” “continue,” “could,” “develop,” “estimate,” “expect,” “intend,” “may,” “opportunity,” “plan,” “potential,” “propose,” “project,” “seek,” “target,” “will,” and similar expressions, or statements that certain events or conditions “may,” “could,” “should,” or “will” occur. These forward-looking statements are based on management’s current beliefs, expectations, assumptions, and estimates as of the date of this news release. Forward-looking statements are subject to significant known and unknown risks, uncertainties, assumptions, and other factors, many of which are beyond the Company’s control, that could cause actual results, performance, achievements, or developments to differ materially from those expressed or implied by such forward-looking statements. Such factors include, without limitation: risks related to research, product development, testing, optimization, validation, and commercialization; the possibility that the Company’s proposed Rapid Breath Test Kit or related technologies may not achieve anticipated performance, sensitivity, accuracy, reliability, or commercial objectives; uncertainty regarding customer acceptance and market adoption of the Company’s technologies; risks associated with the integration of lateral flow assays, collection devices, analytical methods, and other testing components; uncertainty regarding the timing, scope, or outcome of patent applications and intellectual property protection efforts; competition from existing and future products and technologies; manufacturing, supply chain, scaling, and deployment risks; the ability to secure and maintain strategic relationships, laboratory partnerships, reseller arrangements, research collaborations, and commercial agreements; risks associated with intellectual property protection and enforcement; changes in laws, regulations, standards, or governmental policies affecting cannabis, alcohol, workplace testing, diagnostic technologies, or related industries; regulatory approval, clearance, certification, and compliance risks; technological limitations or challenges; dependence on third-party suppliers, laboratories, manufacturers, developers, and service providers; financing and capital market risks; economic, tariff, industry, and market conditions; and the possibility that anticipated opportunities in drug testing, workplace safety, health, diagnostics, breath analysis, or other adjacent markets may not materialize or may not be commercially successful. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements, as actual results and future events may differ materially from those anticipated. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
